Atreca Announces Corporate Reorganization to Extend Cash Runway
June 01, 2022 16:01 ET
|
Atreca, Inc.
Company continuing to advance ATRC-101, ATRC-301 and other oncology pipeline assets Extends cash runway through 2023 and reduces workforce by more than 25% On track to report data from ATRC-101 and...
Atreca to Present at Upcoming Investor Conferences
May 19, 2022 16:30 ET
|
Atreca, Inc.
SAN CARLOS, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments
May 11, 2022 08:00 ET
|
Atreca, Inc.
SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101”
May 04, 2022 16:30 ET
|
Atreca, Inc.
SAN CARLOS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca to Present at Upcoming Virtual Investor Conferences
April 08, 2022 16:05 ET
|
Atreca, Inc.
SAN CARLOS, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...
Atreca Announces Expansion of Preclinical Pipeline
April 05, 2022 16:01 ET
|
Atreca, Inc.
Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate Virtual R&D Day scheduled for today at 4:15 p.m. EDT SAN CARLOS, Calif.,...
Atreca to Host Virtual R&D Day on Tuesday, April 5, 2022
March 23, 2022 08:00 ET
|
Atreca, Inc.
SAN CARLOS, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...
Atreca to Participate in Cowen 42nd Annual Healthcare Conference
March 04, 2022 08:30 ET
|
Atreca, Inc.
SAN CARLOS, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...
Atreca Reports Fourth Quarter and Full-Year 2021 Financial Results and ATRC-101 Data Update
March 03, 2022 16:01 ET
|
Atreca, Inc.
Partial response (PR) observed in ATRC-101 monotherapy cohort as well as a confirmed complete response (CR) observed in pembrolizumab combination cohort in Phase 1b clinical trial Clinical activity...
Atreca to Report Fourth Quarter 2021 Results and Host Year-End Conference Call on March 3, 2022
February 24, 2022 16:30 ET
|
Atreca, Inc.
SAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...